Therapeutic Asset Ratings
396 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
[Ac-225]-Psma-62
Hormone Sensitive Prostate Cancer
Eli Lilly and Company
P1
CC
(43)
CIS-DIAMMINEDICHLOROPLATINUM II
SMARCA4-Deficient Sarcoma Of Thorax
Eli Lilly and Company
P1
CC
(43)
Cyclophosphamide
SMARCA4-Deficient Tumor
Eli Lilly and Company
P1
CC
(43)
Durvalumab
Chondrosarcoma
Eli Lilly and Company
P1
CC
(43)
Epirubicin
SMARCA4-Deficient Tumor
Eli Lilly and Company
P1
CC
(43)
Loxo-260
Thyroid Cancer
Eli Lilly and Company
P1
CC
(43)
Loxo-338
Marginal Zone Lymphoma
Eli Lilly and Company
P1
CC
(43)
Loxo-338
Mantle Cell Lymphoma
Eli Lilly and Company
P1
CC
(43)
Loxo-435
Ureter Neoplasm
Eli Lilly and Company
P1
CC
(43)
Loxo-435
Urinary Bladder Neoplasm
Eli Lilly and Company
P1
CC
(43)
ly3410738
Cancer
Eli Lilly and Company
P1
CC
(43)
ly3410738
Chondrosarcoma
Eli Lilly and Company
P1
CC
(43)
ly3410738
Chronic Myelomonocytic Leukemia
Eli Lilly and Company
P1
CC
(43)
ly3410738
Myelodysplastic Syndrome
Eli Lilly and Company
P1
CC
(43)
ly3885125
Inherited Lipid Metabolism Disorder
Eli Lilly and Company
P1
CC
(43)
ly4050784
SMARCA4-Deficient Sarcoma Of Thorax
Eli Lilly and Company
P1
CC
(43)
ly4052031
Cancer
Eli Lilly and Company
P1
CC
(43)
ly4052031
Renal Pelvis Carcinoma
Eli Lilly and Company
P1
CC
(43)
ly4052031
Urinary Bladder Neoplasm
Eli Lilly and Company
P1
CC
(43)
ly4101174
Cancer
Eli Lilly and Company
P1
CC
(43)
ly4101174
Renal Pelvis Carcinoma
Eli Lilly and Company
P1
CC
(43)
ly4101174
Urinary Bladder Neoplasm
Eli Lilly and Company
P1
CC
(43)
ly4152199 - iv
Marginal Zone Lymphoma
Eli Lilly and Company
P1
CC
(43)
ly4152199 - iv
Follicular Lymphoma
Eli Lilly and Company
P1
CC
(43)
ly4152199 - iv
Mantle Cell Lymphoma
Eli Lilly and Company
P1
CC
(43)
Showing 251 to 275 of 396 assets
Previous
Page 11 of 16
Next
